Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial

• Mitchell S Cairo,
• Stephan Voss,
• Qiuhu Shi,
• Jessica Hochberg,
• Jaclyn Basso,
• Liana Klejmont,
• Allyson Flower,
• Kristina Bortfeld,
• Lauren Harrison,
• Carmella van de Ven,
• Chitti Moorthy,
• Humayun Islam,
• Perry Gerard

Affiliations

Mitchell S Cairo

Department of Pediatrics, Medicine, Pathology, Microbiology and Immunology and Cell Biology, New York Medical College At Maria Fareri Children’s Hospital, New York City, New York, USA

Stephan Voss

Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig Maximilians University Munich, Munich, Germany

Qiuhu Shi

New York Medical College, Valhalla, New York, USA

Jessica Hochberg

Pediatrics, New York Medical College, Valhalla, New York, USA

Jaclyn Basso

Pediatrics, New York Medical College, Valhalla, New York, USA

Liana Klejmont

Pediatrics, New York Medical College, Valhalla, New York, USA

Allyson Flower

Pediatrics, New York Medical College, Valhalla, New York, USA

Kristina Bortfeld

Pediatrics, New York Medical College, Valhalla, New York, USA

Lauren Harrison

Pediatrics, New York Medical College, Valhalla, New York, USA

Carmella van de Ven

Pediatrics, New York Medical College, Valhalla, New York, USA

Chitti Moorthy

Radiology, New York Medical College, Valhalla, New York, USA

Humayun Islam

Pathology, New York Medical College, Valhalla, New York, USA

Perry Gerard

Radiology, New York Medical College, Valhalla, New York, USA